The reported cases provide preliminary human evidence that MEK inhibition with selumetinib can control progressive NF1-associated optic pathway gliomas while improving visual function; it is an inference, not established by this uncontrolled series, that selumetinib could replace or precede conventional chemotherapy as a less toxic first- or second-line treatment.

The trial provides evidence that the glucuronide PARP-inhibitor prodrug TSL-1502 has antitumor activity in BRCA-mutated advanced breast cancer; it remains an inference requiring larger trials that prodrug targeting will improve the therapeutic index or outcomes relative to chemotherapy or established PARP inhibitors, and the record provides no pediatric-specific efficacy or safety evidence.

The randomized trial evidence supports adjuvant pembrolizumab as improving recurrence-free survival in high-risk stage II melanoma; the additional hypothesis that PD-1 blockade may reduce subsequent nonmelanoma skin cancers is plausible from the observed counts but remains inferential because this analysis was not prespecified, and pediatric-specific benefit cannot be determined from the supplied record.

Evidence in the review supports clinically relevant loss of vaccine-associated antibody protection after chemotherapy; it is an inference, not directly tested here, that routine post-chemotherapy booster vaccination irrespective of serological status could improve protection against vaccine-preventable infections.

Evidence supports the hypothesis that first-line intra-arterial chemotherapy may improve eye preservation compared with intravenous chemotherapy in children with retinoblastoma; inferring a preferred regimen or added value from combined intravenous and intra-arterial treatment remains premature because survival, toxicity, recurrence, metastasis, and long-term outcomes are uncertain or inadequately reported.

The supplied evidence supports proton therapy as a clinically used radiotherapy approach with favorable pooled outcomes, while the proposal that modern intensity-modulated proton dose escalation could improve control after subtotal resection remains an untested hypothesis requiring prospective comparative evaluation.

The reported responses support the preliminary hypothesis that tumour stem cell membrane microparticle loading may enhance DC–CIK targeting of refractory T/NK-cell malignancies; however, comparative studies are required to determine whether the cellular product caused the responses, improves durability, or is acceptably safe.

The reported clinical outcomes support seven-day venetoclax plus dose-adjusted intensive chemotherapy as a potentially active induction strategy; it may preserve efficacy while reducing myelosuppression relative to longer venetoclax schedules, but that comparative safety advantage is an inference because no longer-duration control group or detailed toxicity comparison is reported.

The reported comparative response signals support the hypothesis that selected PD-1/PD-L1 inhibitor combinations may improve response rates in Hodgkin lymphoma; however, this is an inference from aggregate and network comparisons, not proof of superiority, safety, survival benefit, or pediatric-specific efficacy.

The trial provides evidence that intermittent cycles of exclusive enteral nutrition can maintain drug-free remission more effectively than low-dose daily partial enteral nutrition in selected pediatric Crohn's disease responders; any relevance to pediatric oncology or treatment-associated gastrointestinal disease would be speculative because no patients with cancer were studied.

The record provides preclinical evidence that restoring reduced glomerular angiopoietin-1 through kidney-targeted mRNA delivery can slow WT1-associated glomerular disease; it remains an inference—not human evidence—that this approach could preserve renal function or delay dialysis or transplantation in affected children.

The evidence supports delivery route as a potential safety and treatment-selection consideration rather than a demonstrated determinant of survival; it can be inferred—but is not established—that systemic delivery may sometimes reduce severe neurotoxicity without compromising survival, pending platform-specific comparative studies.